-

Stanford Medicine and Stanford Institute for Human-Centered Artificial Intelligence announce RAISE-Health, a responsible AI initiative

STANFORD, Calif.--(BUSINESS WIRE)--Responding to rapid advances in artificial intelligence and the urgent need to define its responsible use in health and medicine, Stanford Medicine and the Stanford Institute for Human-Centered Artificial Intelligence (HAI) today announced the launch of RAISE-Health (Responsible AI for Safe and Equitable Health). This pioneering initiative seeks to address critical ethical and safety issues surrounding AI innovation and help others navigate this complex and evolving field.

Co-led by Stanford School of Medicine dean Lloyd Minor, MD, and Stanford HAI co-director and computer science professor Fei-Fei Li, PhD, the new initiative will establish a go-to platform for responsible AI in health and medicine; define a structured framework for ethical standards and safeguards; and regularly convene a diverse group of multidisciplinary innovators, experts and decision makers on the topic.

Both awareness of AI and skepticism about its use in health care have skyrocketed in the last 12 months. According to a recent Pew survey, a majority of Americans said they would be uncomfortable with their provider using AI in their own health care, underscoring the crossroads at which society finds itself.

“AI has the potential to impact every aspect of health and medicine,” Minor said. “We have to act with urgency to ensure that this technology advances in line with the interests of everyone, from the research bench to the patient bedside and beyond.”

Goals of the RAISE-Health initiative include enhancing clinical care outcomes through responsible integration of AI; accelerating research to solve for the biggest challenges in health and medicine; and educating patients, care providers and researchers to navigate AI advances.

“AI is evolving at an incredible pace; so, too, must our capacity to manage, navigate and direct its path,” said Li, whose research includes a focus on ambient intelligence — using AI to monitor and respond to human activity in homes, hospitals and other environments. “Through this initiative, we are seeking to engage our students, our faculty and the broader community to help shape the future of AI, ensuring it reflects the interests of all stakeholders — patients, families and society at large.”

Building on the goals of Stanford HAI, groundbreaking Stanford faculty research and ongoing collaborations with policymakers and Silicon Valley innovators, RAISE-Health will be a trusted repository for the AI work being done at Stanford University, Stanford Medicine and well beyond — hosting standards, tools, models, data, research and best practices.

While AI offers the potential for transforming health globally, decision makers must first address AI’s safety and ethical use to responsibly harness its full potential and build public trust in these systems.

About Stanford Medicine

Stanford Medicine is an integrated academic health system comprising the Stanford School of Medicine and adult and pediatric health care delivery systems. Together, they harness the full potential of biomedicine through collaborative research, education and clinical care for patients. For more information, please visit med.stanford.edu.

About the Stanford Institute for Human-Centered Artificial Intelligence

The mission of HAI is to advance AI research, education, policy and practice to improve the human condition. Led by faculty from multiple departments across Stanford, research focuses on developing AI technologies inspired by human intelligence; studying, forecasting and guiding the human and societal impact of AI; and designing and creating AI applications that augment human capabilities. Through the education work of the institute, students and leaders at all stages gain a range of AI fundamentals and perspectives. At the same time, the policy work of HAI fosters regional and national discussions that lead to direct legislative impact.

Contacts

Media contact:
Lisa Kim
(650) 723-6696 (likim@stanfordhealthcare.org)

Stanford Medicine


Release Versions

Contacts

Media contact:
Lisa Kim
(650) 723-6696 (likim@stanfordhealthcare.org)

More News From Stanford Medicine

Stanford Medicine to Launch the Patients Like MineSM Suite of Services, Empowering Community Physicians with Data and Reference Solutions

STANFORD, Calif.--(BUSINESS WIRE)--Stanford Medicine is launching the Patients Like MineSM, suite of services specifically designed to equip community physicians in diverse practice settings with the data and reference solutions to assist them in delivering evidence-based, high-quality care to their patients. Patients Like MineSM services will enable community physicians to leverage Stanford Medicine’s digital tools, large language models and artificial intelligence-enabled services while prese...

Stanford Medicine and Northpond Ventures Announce the Launch of The Northpond Laboratories - Program for Research and Innovation at Stanford Medicine

STANFORD, Calif.--(BUSINESS WIRE)--Stanford Medicine and Northpond Ventures announced the launch of The Northpond Laboratories - Program for Research and Innovation at Stanford Medicine. The program seeks to identify and build upon the scientific discoveries and innovations developed by Stanford Medicine's leading faculty and researchers and accelerate the pace of translation between scientific research to clinical and commercial applications that improve patient outcomes through the vehicle of...

Stanford University’s Innovative Medicines Accelerator and Intonation Research Laboratories (Intonation) form a collaboration to fight cancerous neuroendocrine tumors

STANFORD, Calif.--(BUSINESS WIRE)--Stanford University’s Innovative Medicines Accelerator (IMA) and Intonation Research Laboratories (Intonation) have formed a collaboration to develop treatments that target cancerous neuroendocrine tumors, or tumors that form from hormone-releasing cells. The goal of the collaboration is to reduce the time and resources it takes to translate a biomedical breakthrough into a clinically and commercially viable medicine. “I’m excited about this collaboration with...
Back to Newsroom